重组人红细胞生成素在肾移植病人中的应用  

APPLICATION OF RECOMBINANT HUMAN ERYTHROPOIETIN IN KIDNEY RECIPIENTS

作　　者：张红妹[1] 胡明明[1] 王祥花[1] 李海燕[1] 黄静[1] 傅玲[1] 

机构地区：[1]青岛大学医学院附属医院泌尿外科,山东青岛266003

出　　处：《齐鲁医学杂志》2006年第4期347-348,共2页Medical Journal of Qilu

摘　　要：目的评估肾移植术前、术后应用重组人红细胞生成素（rHuEPO）对移植肾功能的影响，以及对肾移植术后贫血的纠正作用。方法病人随机分为3组。A组术前术后均未接受rHuEPO治疗，B组在肾移植术前接受rHuEPO治疗，C组肾移植术后早期接受rHuEP0治疗，当红细胞压积（Hct）〈0．30时开始应用rHuEPO治疗。结果rHuEPO治疗后的血红蛋白（Hb）均明显升高，以C组最高（F=43．51、88．79，q=3．27～18．85，P〈0．05）；B、C组术后肾功能延迟恢复和急性排斥反应的发生率与A组比较差异无显著性（P〉0．05）。结论在肾移植手术后早期应用rHuEPO对纠正贫血是有益的，而且不会增加肾功能延迟恢复和急性排斥反应的发生率。Objective To assess the effects of pre- or postoperative application of recombinant human erythropoietin （rHuEPO） on graft function and postoperative anemia in patients undergoing renal transplantation. Methods The patients were randomly divided into three groups： group A, no rHuEPO was used, group B, preoperative rHuEPO, and group C, postoperative rHuEPO, in which, rHuEPO was given when HCT was less than 0.30 postoperatively. Results Hb was significantly increased after rHuEPO treatment （F=43.51,88.79,q=3.27-18.85; P〈0.05）, group C being the highest. There was no difference between the three groups in terms of delayed renal function and acute rejection. Conclusion The use of rHuEPO during the early stage after transplantation is helpful in the correction of anaemia without increasing the incidence of acute rejection and delayed graft function.

关 键 词：红细胞生成素 重组 肾移植 贫血 

分 类 号：R617[医药卫生—外科学]